HEALTH CANADA OKS SCHERING DRUG FOR EARLY STAGE MS DISEASE

German pharmaceutical company Schering AG Thursday said its Betaferon drug has been approved by the Health Products and Food Branch of Health Canada, thereby extending the drug's use to now include patients in the earliest stages of multiple sclerosis, MS. With this approval, Betaferon becomes the highest-dose highest-frequency therapy approved for the treatment of the earliest stages of MS in Canada. The approval provides an important treatment option for patients to reduce the risk of developing clinically definite MS, or CDMS, and the potential to delay the progression of the disease.

Easy Bourse (http://www.easybourse.com/Website/dynamic/News.php?NewsID=36494&lang=fra&NewsRubrique=2)